NO20062883L - Fosfodiesterase-V-inhibitorpreparater - Google Patents

Fosfodiesterase-V-inhibitorpreparater

Info

Publication number
NO20062883L
NO20062883L NO20062883A NO20062883A NO20062883L NO 20062883 L NO20062883 L NO 20062883L NO 20062883 A NO20062883 A NO 20062883A NO 20062883 A NO20062883 A NO 20062883A NO 20062883 L NO20062883 L NO 20062883L
Authority
NO
Norway
Prior art keywords
inhibitorpreparater
phosphodiesterase
pde
women
inhibitors
Prior art date
Application number
NO20062883A
Other languages
English (en)
Norwegian (no)
Inventor
Surendra A Sangekar
Zhiyun Wang
Ping I Lee
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34632926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062883(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20062883L publication Critical patent/NO20062883L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/18—Processes for applying liquids or other fluent materials performed by dipping
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D7/00—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
    • B05D7/14—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials to metal, e.g. car bodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2202/00—Metallic substrate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2258/00—Small objects (e.g. screws)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NO20062883A 2003-11-21 2006-06-20 Fosfodiesterase-V-inhibitorpreparater NO20062883L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52473103P 2003-11-21 2003-11-21
PCT/US2004/038887 WO2005051368A2 (en) 2003-11-21 2004-11-18 Phosphodiesterase v inhibitor formulations

Publications (1)

Publication Number Publication Date
NO20062883L true NO20062883L (no) 2006-08-18

Family

ID=34632926

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062883A NO20062883L (no) 2003-11-21 2006-06-20 Fosfodiesterase-V-inhibitorpreparater

Country Status (15)

Country Link
US (2) US20060040962A1 (pt)
EP (1) EP1691788A2 (pt)
JP (1) JP2007512345A (pt)
KR (1) KR20060101762A (pt)
CN (1) CN1905860A (pt)
AR (1) AR047948A1 (pt)
AU (1) AU2004292991A1 (pt)
BR (1) BRPI0416202A (pt)
CA (1) CA2546248A1 (pt)
MX (1) MXPA06005681A (pt)
NO (1) NO20062883L (pt)
PE (1) PE20050985A1 (pt)
TW (1) TW200526664A (pt)
WO (1) WO2005051368A2 (pt)
ZA (1) ZA200604025B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546786A (ja) * 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
WO2008021347A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
EP2316422A1 (en) * 2007-11-12 2011-05-04 Novartis AG Liquid compositions comprising valsartan
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
JP6002562B2 (ja) * 2012-12-05 2016-10-05 横浜ゴム株式会社 面ファスナー付き空気入りタイヤ及びその製造方法
CU24638B1 (es) * 2020-02-03 2023-01-16 Centro Nac De Investigaciones Cientificas Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon
CA3229279A1 (en) * 2022-02-14 2023-02-16 Onyx Lotus, Llc Powder disinfectant compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057628A (en) * 1976-04-19 1977-11-08 William L. Wilson Removal of hepatitis associated antigen from plasma
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
NZ238609A (en) * 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
ES2148170T3 (es) * 1990-12-21 2000-10-16 Beecham Group Plc Derivados de xantina.
EP0686157A1 (en) * 1993-02-26 1995-12-13 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5470479A (en) * 1994-06-23 1995-11-28 Westinghouse Electric Corporation Continuous, steady-state, chromatographic separation of gadolinium isotopes
HU227841B1 (en) * 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
JP3290970B2 (ja) * 1998-07-22 2002-06-10 山之内製薬株式会社 難溶性ＮＳＡＩＤｓ含有固形製剤
US20030153623A1 (en) * 1998-07-22 2003-08-14 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble NSAIDs
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US6491950B1 (en) * 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
JP3470096B2 (ja) * 2000-09-19 2003-11-25 沢井製薬株式会社 ニルバジピン含有易溶性固形製剤およびその製造法
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
JP4450365B2 (ja) * 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼｖ阻害剤
CN1585771A (zh) * 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
AU2002359857B8 (en) * 2001-12-28 2009-01-08 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
JP2005529933A (ja) * 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビター多形体
CN101538224A (zh) * 2002-05-31 2009-09-23 先灵公司 制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives

Also Published As

Publication number Publication date
ZA200604025B (en) 2008-01-30
AR047948A1 (es) 2006-03-15
KR20060101762A (ko) 2006-09-26
PE20050985A1 (es) 2005-11-26
US20090074869A1 (en) 2009-03-19
TW200526664A (en) 2005-08-16
WO2005051368A2 (en) 2005-06-09
AU2004292991A1 (en) 2005-06-09
EP1691788A2 (en) 2006-08-23
BRPI0416202A (pt) 2006-12-26
MXPA06005681A (es) 2006-08-17
WO2005051368A3 (en) 2006-03-09
CN1905860A (zh) 2007-01-31
US20060040962A1 (en) 2006-02-23
JP2007512345A (ja) 2007-05-17
CA2546248A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
MY128479A (en) (beta)-carboline derivatives useful as inhibitors of phosphodiesterase
ZA200704476B (en) Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
EA200600064A1 (ru) Производные тиенопиридона как ингибиторы киназ
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AR016993A1 (es) Formulaciones intranasales para tratar trastornos sexuales
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
TR200003039T2 (tr) Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri
PT1687305E (pt) Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
EA200200337A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[4,3-d]ПИРИМИДИНА
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
NO20005661L (no) Komponenter for behandlingen av kvinnelig seksuell dysfunksjon
TW200607803A (en) Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
NO20092145L (no) Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon
WO2005056547A3 (en) Quinoxalines useful as inhibitors of protein kinases
SE0002934D0 (sv) New aporphine esters and in their use in therapy
SG10201903619YA (en) Carbazole derivatives
TN2014000492A1 (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
NO20024364D0 (no) Anvendelse av pyrido [3,2-E]-pyrazinoner som inhibitorer av fosfodiesterase 5 for behandling av erektil dysfunksjon
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
DE60226970D1 (de) Pyrazinoä1',2':1,6ü-pyridoä3,4-bü indole-1,4-dionderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application